title: In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
abstract: Telavancin is a novel, rapidly cidal, dual-action glycopeptide. This study examined its in vitro activity against relevant Gram-positive pathogens, comprising 99 meticillin-resistant Staphylococcus aureus (MRSA), 40 meticillin-susceptible S. aureus (MSSA), 79 coagulase-negative staphylococci (CoNS), 45 Enterococcus faecalis, 60 Enterococcus faecium, 40 β-haemolytic streptococci and 60 Streptococcus pneumoniae. Except with VanA enterococci, telavancin MICs were tightly clustered and unimodal. Telavancin MICs for staphylococci ranged from ≤0.03 mg/L to 0.5mg/L, with no shift for MRSA or MSSA in relation to vancomycin MIC. Nevertheless, and independently of species, CoNS with raised vancomycin MICs had reduced susceptibility to telavancin, however this was much more marked for teicoplanin. Modal telavancin MICs were 0.5mg/L and ≤0.03 mg/L for glycopeptide-susceptible E. faecalis and E. faecium, respectively, with no rise for VanB isolates, but ranges rose to 4-16 mg/L and 1-4 mg/L for VanA isolates, respectively. Streptococci were consistently susceptible, with MICs of ≤0.06 mg/L. Telavancin MICs by Etest agreed within 1 doubling dilution with those found previously by BSAC agar dilution in 96.2% of cases, although with slight bias towards lower values. In the few cases (13/345) where telavancin MICs by Etest were ≥2 doubling dilutions different from those by agar dilution, the Etest value was always lower; this effect was greater for the other antibiotics tested. Telavancin had excellent activity, except against enterococci with VanA, with no erosion of this activity against MRSA with raised vancomycin MICs. MICs by Etest were nearly always within 1 dilution of those by BSAC agar dilution.
authors.affiliation: Antibiotic Resistance Monitoring & Reference Laboratory, Microbiology Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK. russell.hope@hpa.org.uk
authors.forename: Russell
authors.initials: R
authors.lastname: Hope
authors.forename: Aiysha
authors.initials: A
authors.lastname: Chaudhry
authors.forename: Rachael
authors.initials: R
authors.lastname: Adkin
authors.forename: David M
authors.initials: DM
authors.lastname: Livermore
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016983:Enterococcus / Q000187:drug effects* / Q000302:isolation & purification; D006095:Gram-Positive Cocci / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D013210:Staphylococcus / Q000187:drug effects* / Q000302:isolation & purification; D013291:Streptococcus / Q000187:drug effects* / Q000302:isolation & purification
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin